BioCentury
ARTICLE | Product Development

COVID-19 Quick Takes: AZ starts pivotal study of vaccine as Pfizer, BioNTech pass two-thirds enrollment mark

September 1, 2020 1:54 AM UTC

AZ begins U.S. Phase III vaccine study
AstraZeneca plc (LSE:AZN; NYSE:AZN) announced Monday the beginning of the 30,000-volunteer U.S. Phase III D8110C00001 trial of AZD1222 to prevent COVID-19. The U.S. Biomedical Advanced Development Authority (BARDA) is financially supporting the study evaluating prime-boost administration of the adenovirus vector vaccine. The estimated primary completion date of the double-blind study is Dec. 2, according to ClinicalTrials.gov (see “Operation Warp Speed Commitments”).

Pfizer, BioNTech pivotal vaccine trial over two thirds enrolled
Pfizer Inc. (NYSE:PFE) and partner BioNTech SE (NASDAQ:BNTX) have enrolled over 20,000 of the target 30,000 subjects in their Phase II/III trial of BNT162b2, Pfizer EVP and Chief Development Officer Rod MacKenzie told BioCentury. MacKenzie added the 20,000 have received the first immunization of two of the mRNA COVID-19 vaccine...